165 related articles for article (PubMed ID: 18178807)
1. Blockade of CD200 in the presence or absence of antibody effector function: implications for anti-CD200 therapy.
Kretz-Rommel A; Qin F; Dakappagari N; Cofiell R; Faas SJ; Bowdish KS
J Immunol; 2008 Jan; 180(2):699-705. PubMed ID: 18178807
[TBL] [Abstract][Full Text] [Related]
2. CD200 expression on tumor cells suppresses antitumor immunity: new approaches to cancer immunotherapy.
Kretz-Rommel A; Qin F; Dakappagari N; Ravey EP; McWhirter J; Oltean D; Frederickson S; Maruyama T; Wild MA; Nolan MJ; Wu D; Springhorn J; Bowdish KS
J Immunol; 2007 May; 178(9):5595-605. PubMed ID: 17442942
[TBL] [Abstract][Full Text] [Related]
3. The role of CD200 in immunity to B cell lymphoma.
Wong KK; Khatri I; Shaha S; Spaner DE; Gorczynski RM
J Leukoc Biol; 2010 Aug; 88(2):361-72. PubMed ID: 20442224
[TBL] [Abstract][Full Text] [Related]
4. IL-2Ralpha-Directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ralpha interaction.
Phillips KE; Herring B; Wilson LA; Rickford MS; Zhang M; Goldman CK; Tso JY; Waldmann TA
Cancer Res; 2000 Dec; 60(24):6977-84. PubMed ID: 11156399
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of CD200 is a Stem Cell-Specific Mechanism of Immune Evasion in AML.
Herbrich S; Baran N; Cai T; Weng C; Aitken MJL; Post SM; Henderson J; Shi C; Richard-Carpentier G; Sauvageau G; Baggerly K; Al-Atrash G; Davis RE; Daver N; Zha D; Konopleva M
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34326171
[TBL] [Abstract][Full Text] [Related]
6. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
[TBL] [Abstract][Full Text] [Related]
7. Human anti-CAIX antibodies mediate immune cell inhibition of renal cell carcinoma in vitro and in a humanized mouse model in vivo.
Chang DK; Moniz RJ; Xu Z; Sun J; Signoretti S; Zhu Q; Marasco WA
Mol Cancer; 2015 Jun; 14():119. PubMed ID: 26062742
[TBL] [Abstract][Full Text] [Related]
8. Immune modulation by melanoma and ovarian tumor cells through expression of the immunosuppressive molecule CD200.
Siva A; Xin H; Qin F; Oltean D; Bowdish KS; Kretz-Rommel A
Cancer Immunol Immunother; 2008 Jul; 57(7):987-96. PubMed ID: 18060403
[TBL] [Abstract][Full Text] [Related]
9. Role of CD200 expression in regulation of metastasis of EMT6 tumor cells in mice.
Gorczynski RM; Clark DA; Erin N; Khatri I
Breast Cancer Res Treat; 2011 Nov; 130(1):49-60. PubMed ID: 21165772
[TBL] [Abstract][Full Text] [Related]
10. Further evidence for a role of tumor CD200 expression in breast cancer metastasis: decreased metastasis in CD200R1KO mice or using CD200-silenced EMT6.
Podnos A; Clark DA; Erin N; Yu K; Gorczynski RM
Breast Cancer Res Treat; 2012 Nov; 136(1):117-27. PubMed ID: 23053647
[TBL] [Abstract][Full Text] [Related]
11. Disruption of T cell suppression in chronic lymphocytic leukemia by CD200 blockade.
Pallasch CP; Ulbrich S; Brinker R; Hallek M; Uger RA; Wendtner CM
Leuk Res; 2009 Mar; 33(3):460-4. PubMed ID: 18838168
[TBL] [Abstract][Full Text] [Related]
12. Soluble CD200 is critical to engraft chronic lymphocytic leukemia cells in immunocompromised mice.
Wong KK; Brenneman F; Chesney A; Spaner DE; Gorczynski RM
Cancer Res; 2012 Oct; 72(19):4931-43. PubMed ID: 22875025
[TBL] [Abstract][Full Text] [Related]
13. Breast cancer cell CD200 expression regulates immune response to EMT6 tumor cells in mice.
Gorczynski RM; Chen Z; Diao J; Khatri I; Wong K; Yu K; Behnke J
Breast Cancer Res Treat; 2010 Sep; 123(2):405-15. PubMed ID: 19953316
[TBL] [Abstract][Full Text] [Related]
14. Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody.
Stewart R; Morrow M; Hammond SA; Mulgrew K; Marcus D; Poon E; Watkins A; Mullins S; Chodorge M; Andrews J; Bannister D; Dick E; Crawford N; Parmentier J; Alimzhanov M; Babcook JS; Foltz IN; Buchanan A; Bedian V; Wilkinson RW; McCourt M
Cancer Immunol Res; 2015 Sep; 3(9):1052-62. PubMed ID: 25943534
[TBL] [Abstract][Full Text] [Related]
15. Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide.
Takahashi N; Haba A; Matsuno F; Seon BK
Cancer Res; 2001 Nov; 61(21):7846-54. PubMed ID: 11691802
[TBL] [Abstract][Full Text] [Related]
16. Use of an anti-CD200-blocking antibody improves immune responses to AML in vitro and in vivo.
Rastogi N; Baker S; Man S; Uger RA; Wong M; Coles SJ; Hodges M; Gilkes AF; Knapper S; Darley RL; Tonks A
Br J Haematol; 2021 Apr; 193(1):155-159. PubMed ID: 32996123
[TBL] [Abstract][Full Text] [Related]
17. Novel immunotherapy for malignant melanoma with a monoclonal antibody that blocks CEACAM1 homophilic interactions.
Ortenberg R; Sapir Y; Raz L; Hershkovitz L; Ben Arav A; Sapoznik S; Barshack I; Avivi C; Berkun Y; Besser MJ; Ben-Moshe T; Schachter J; Markel G
Mol Cancer Ther; 2012 Jun; 11(6):1300-10. PubMed ID: 22466331
[TBL] [Abstract][Full Text] [Related]
18. Defucosylated anti-CCR4 monoclonal antibody exerts potent ADCC against primary ATLL cells mediated by autologous human immune cells in NOD/Shi-scid, IL-2R gamma(null) mice in vivo.
Ito A; Ishida T; Utsunomiya A; Sato F; Mori F; Yano H; Inagaki A; Suzuki S; Takino H; Ri M; Kusumoto S; Komatsu H; Iida S; Inagaki H; Ueda R
J Immunol; 2009 Oct; 183(7):4782-91. PubMed ID: 19748990
[TBL] [Abstract][Full Text] [Related]
19. [Monoclonal antibody against brain derived neurotrophic factor inhibits myeloma growth and angiogenesis in the xenograft NOD/SCID animal model].
Wang YD; Hu Y; Zhang L; Huang J; Sun CY
Zhonghua Xue Ye Xue Za Zhi; 2007 Oct; 28(10):659-63. PubMed ID: 18399169
[TBL] [Abstract][Full Text] [Related]
20. Development of a new high-affinity human antibody with antitumor activity against solid and blood malignancies.
Sioud M; Westby P; Vasovic V; Fløisand Y; Peng Q
FASEB J; 2018 Sep; 32(9):5063-5077. PubMed ID: 29913558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
